UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

The lancet oncology, 2013-04, Vol.14 (4), p.306-316

2013

Volltextzugriff (PDF)

Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer

Journal of endourology, 2012-05, Vol.26 (5), p.503-508

2012

Volltextzugriff (PDF)

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

European urology, 2016-06, Vol.69 (6), p.1016-1025

2016

Volltextzugriff (PDF)

Tumor focality in prostate cancer: implications for focal therapy

Nature reviews. Clinical oncology, 2011-01, Vol.8 (1), p.48-55

2011

Volltextzugriff (PDF)

Extending the case for oestradiol in androgen-sensitive prostate cancer – Authors' reply

The lancet oncology, 2013-06, Vol.14 (7), p.e253-e253

2013

Volltextzugriff (PDF)

TFF2 (trefoil family factor2) inhibits apoptosis in breast and colorectal cancer cell lines

Peptides (New York, N.Y. : 1980), 2004-05, Vol.25 (5), p.855-863

2004

Volltextzugriff (PDF)

Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?

Nature reviews. Urology, 2017-09, Vol.14 (9), p.575-575

2017

Volltextzugriff (PDF)

Gonadal suppression alters axillary steroid secretions in men, but does that affect olfactory social signaling?

Journal of Men’s Health, 2021-01

2021

Volltextzugriff (PDF)

Ligand Activation of the Androgen Receptor Downregulates E-Cadherin-Mediated Cell Adhesion and Promotes Apoptosis of Prostatic Cancer Cells

Neoplasia (New York, N.Y.), 2003-07, Vol.5 (4), p.347-361

2003

Volltextzugriff (PDF)

Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675–91

European urology, 2011-04, Vol.59 (4), p.e24-e25

2011

Volltextzugriff (PDF)

Trends in pathologic outcomes after introduction of active surveillance in the UK: Implication for focal therapy

The Prostate, 2012-09, Vol.72 (13), p.1464-1468

2012

Volltextzugriff (PDF)

Osteoporosis in patients with prostate cancer on long‐term androgen deprivation therapy: an increasing but under‐recognised problem

BJU international, 2010-09, Vol.106 (5), p.726-727

2010

Volltextzugriff (PDF)

Survival of patients with bladder cancer from a UK hospital: a 10‐year follow‐up study

BJU international, 2010-06, Vol.105 (12), p.1667-1671

2010

Volltextzugriff (PDF)

Oestrogen patches (OP) to treat prostate cancer (PC) – Are different commercial brands interchangeable?

Maturitas, 2015-05, Vol.81 (1), p.210-211

2015

Volltextzugriff (PDF)

Parenteral oestrogen: Effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?

Scandinavian journal of urology, 2014-08, Vol.48 (4), p.411-412

2014

Volltextzugriff (PDF)

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first‐line hormonal therapy in patients with locally advanced or metastatic prostate cancer

BJU international, 2008-08, Vol.102 (4), p.442-445

2008

Volltextzugriff (PDF)

Re: Androgen Deprivation Therapy: Impact on Quality of Life and Cardiovascular Health

Journal of sexual medicine, 2014-01, Vol.11 (1), p.314-315

2014

Volltextzugriff (PDF)

Use of transdermal estrogen in the management of advanced prostate cancer

Urologic oncology, 2013-02, Vol.31 (2), p.279-279

2013

Volltextzugriff (PDF)

Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study--how useful is the current clinical gold standard for fracture risk?

Clinical interventions in aging, 2015-01, Vol.10, p.1653-1654

2015

Volltextzugriff (PDF)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture

Central European journal of urology, 2015-01, Vol.68 (2), p.165-168

2015

Volltextzugriff (PDF)

Re: Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner J Urol 2010;184:1316–1321

The Journal of urology, 2011-06, Vol.185 (6), p.2430-2432

2011

Volltextzugriff (PDF)

Reproducibility of Quantitative Assessment of Altered Hepatic Hemodynamics With Dynamic Contrast‐Enhanced Ultrasound

Journal of ultrasound in medicine, 2012-09, Vol.31 (9), p.1413-1420

2012

Volltextzugriff (PDF)

Re: Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

The Journal of urology, 2011, Vol.185 (6), p.2430-2432

2011

Volltextzugriff (PDF)

Long term androgen deprivation therapy in prostate cancer

BMJ, 2008-10, Vol.337 (sep22 1), p.a1361-a1361

International edition, 2008

Volltextzugriff (PDF)

1 – 25 von 389

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(330)
Mit Volltextzugriff
(295)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

Quality‐of‐life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone‐releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer

Tumor focality in prostate cancer: implications for focal therapy

Extending the case for oestradiol in androgen-sensitive prostate cancer – Authors' reply

TFF2 (trefoil family factor2) inhibits apoptosis in breast and colorectal cancer cell lines

Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?

Gonadal suppression alters axillary steroid secretions in men, but does that affect olfactory social signaling?

Ligand Activation of the Androgen Receptor Downregulates E-Cadherin-Mediated Cell Adhesion and Promotes Apoptosis of Prostatic Cancer Cells

Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675–91

Trends in pathologic outcomes after introduction of active surveillance in the UK: Implication for focal therapy

Osteoporosis in patients with prostate cancer on long‐term androgen deprivation therapy: an increasing but under‐recognised problem

Survival of patients with bladder cancer from a UK hospital: a 10‐year follow‐up study

Oestrogen patches (OP) to treat prostate cancer (PC) – Are different commercial brands interchangeable?

Parenteral oestrogen: Effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first‐line hormonal therapy in patients with locally advanced or metastatic prostate cancer

Re: Androgen Deprivation Therapy: Impact on Quality of Life and Cardiovascular Health

Use of transdermal estrogen in the management of advanced prostate cancer

Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study--how useful is the current clinical gold standard for fracture risk?

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture

Re: Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner J Urol 2010;184:1316–1321

Reproducibility of Quantitative Assessment of Altered Hepatic Hemodynamics With Dynamic Contrast‐Enhanced Ultrasound

Re: Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Long term androgen deprivation therapy in prostate cancer

Suchergebnisse filtern